TP53 and B-cell chronic lymphocytic leukemia: This heterogeneity may also play a role in resistance, as seen with the 17p deletion, which is not only associated with advanced disease/poor prognosis but also correlated with resistance, as one study found 7 out of 11 venetoclax-resistant CLL patients harbored the TP53 aberration[18,32].